Company Overview
Snapshot
Founded in September 2023, LifeCord operates with 1–10 employees and has raised $1.3 million across two funding rounds from three investors.
Business overview
LifeCord is a Health Tech & Life Sciences company developing a Transfemoral Mitral Chordal Repair system. This core technology addresses the significant challenge of mitral regurgitation by offering a minimally invasive transcatheter solution. The company operates within the medical devices sector, specifically focusing on medical treatment and therapeutics for cardiology and heart diseases, targeting healthcare providers.
Strategic signal
This funding is crucial for advancing their minimally invasive transcatheter system, positioning the company to disrupt the $2 billion mitral valve intervention market by offering a safer alternative to open-heart surgery and preserving the mitral leaflet for future interventions.
Log in to access full profile ›Company Intelligence Q&A
- What is LifeCord's primary focus in the medical device market?
- LifeCord develops a Transfemoral Mitral Chordal Repair system designed to treat degenerative mitral regurgitation (DMR) with a minimally invasive transcatheter approach, offering an alternative to open-heart surgery.
- What was the total capital raised by LifeCord to date?
- LifeCord has raised a total of $1.3 million across its funding rounds.
- What strategic partnerships has LifeCord established?
- LifeCord has established strategic partnerships with MEDX Xelerator and a leading U.S. healthcare institution to support its research and development efforts and market entry.
- What is the intended use of the funding LifeCord received in April 2024?
- The funding secured in April 2024, from investors including Israel Innovation Authority and MEDX Xelerator, is intended to support the completion of First-in-Human trials and further R&D efforts for LifeCord's mitral chordal repair system.